Transforming
Treatment of Severe
Blood Disorders

learn more »

Committed to Serving Patients and Their Families

learn more »

About GBT

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.

more »

Innovative Science

We are passionate and committed to developing our product candidate GBT440, an oral, once-daily therapy that is designed to modulate hemoglobin affinity for oxygen. GBT440 has the potential to treat sickle cell disease and improve hypoxemia in idiopathic pulmonary fibrosis.

more »